$CME

SHEPARD WILLIAM R purchased $3K of CME

SHEPARD WILLIAM R purchased 14 shares of CME GROUP INC. (CME) at $230.57 on 2026-06-25.

Original reporting
SEC EDGAR · SHEPARD WILLIAM R
Published Jun 29, 2026, 8:28 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 29, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CME
Neutral
high confidence
Mentioned
$CME
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CMENeutralLow
01

Why it matters

The newest fact is the director’s open-market purchase details (14 shares at $230.57) and post-transaction holdings (3,621 shares).

02

Market read

Traders may note the insider buy, but the transaction is small and does not introduce new operational or financial information.

03

What to watch

No 10b5-1 plan is stated, but the filing lacks context on intent, timing constraints, or whether this is part of a broader pattern.

Relevance 4/10Novelty 3/10Timing: after-hours/filing timestamp 2026-06-29; reflects 2026-06-25 purchase

Background

The article is an SEC Form 4 insider transaction disclosure for CME Group Inc.

Company-level read

Ticker impact

$CMENeutralHigh confidence
Context

SEC Form 4 shows director SHEPARD WILLIAM R bought 14 shares of CME at $230.57 on 2026-06-25, totaling $3,301.30.

Expected impact

Likely minimal near-term impact; any effect is sentiment-only and small.

Evidence & confidence

The filing is a small, non-material insider buy (14 shares) with no 10b5-1 plan and no accompanying company news.

Market effects

None; this is company-specific insider transaction with no sector datapoint.

None indicated.

None indicated.

Counterpoint

A director purchase can be interpreted as confidence, but the disclosed size is too small to meaningfully change valuation expectations.

Key entities

  • CME Group Inc.

    Subject of the Form 4 insider transaction disclosure.

  • SHEPARD WILLIAM R

    Director who reported the open-market purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CMEMed

CFTC asks judge to toss CME challenge to Kalshi perps

The CFTC urged a judge to dismiss CME's lawsuit challenging its approval of Kalshi's bitcoin perpetual futures, arguing CME lacks standing and that perpetual futures are futures, not swaps. The CFTC claims CME has not shown financial harm and could offer similar products itself. The dispute may extend into the next administration if the judge only rules on standing.

$CMELow

CFTC Asks Judge to Dismiss CME Lawsuit Over Crypto Perpetual Futures

The CFTC asked a judge to dismiss CME's lawsuit over the approval of Kalshi's Bitcoin perpetual futures. The CFTC argued CME showed no financial harm or increased competition. CME claims the contracts should be classified as swaps, not futures. Kalshi and Polymarket plan to expand into perpetual futures, with Kalshi filing for contracts tied to 12 altcoins.

$CMELow

CFTC Moves to Kill CME Lawsuit Over Kalshi’s Bitcoin Perpetual Futures

The CFTC asked a court to dismiss CME Group's lawsuit challenging its approval of Kalshi's Bitcoin perpetual futures (BTCPERP). CME argues these should be classified as swaps, but the CFTC claims CME lacks standing and cites its own data showing increased Bitcoin futures volumes. The case hinges on the treatment of perpetual contracts, with CME favoring swap classification and the CFTC arguing they can be futures. A decision could impact crypto derivatives markets.

$CMELow

CFTC Seeks Dismissal of CME's Crypto Futures Lawsuit, Citing Lack of Standing

The CFTC filed to dismiss CME Group's lawsuit over crypto perpetual futures, arguing CME lacks standing and suffered no significant harm. The CFTC claims CME's alleged harm is 'self-inflicted' and that other exchanges could offer similar products. CME sued in June 2026, seeking to regulate perpetuals as swaps. The case could impact derivatives markets and regulations.

$CMELow

CME Launches Crypto Index That Excludes Bitcoin and Ether

CME Group launched two new cryptocurrency indexes, one excluding Bitcoin and Ether, tracking 10 assets, and another including them. Both use free-float market-cap weighting and are rebalanced semiannually. The indexes are designed for financial products and derivatives, with real-time and daily settlement values.